PT2644698T - Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue - Google Patents
Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangueInfo
- Publication number
- PT2644698T PT2644698T PT118421452T PT11842145T PT2644698T PT 2644698 T PT2644698 T PT 2644698T PT 118421452 T PT118421452 T PT 118421452T PT 11842145 T PT11842145 T PT 11842145T PT 2644698 T PT2644698 T PT 2644698T
- Authority
- PT
- Portugal
- Prior art keywords
- function
- binding molecule
- factor viii
- specific antigen
- blood coagulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010257022 | 2010-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2644698T true PT2644698T (pt) | 2018-01-31 |
Family
ID=46084097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT118421452T PT2644698T (pt) | 2010-11-17 | 2011-11-17 | Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue |
Country Status (29)
Country | Link |
---|---|
US (9) | US9334331B2 (pt) |
EP (2) | EP3318633A1 (pt) |
JP (7) | JP6013915B2 (pt) |
KR (4) | KR101398363B1 (pt) |
CN (2) | CN103298937B (pt) |
AU (2) | AU2011330184B2 (pt) |
BR (1) | BR112013012213A2 (pt) |
CA (1) | CA2817964C (pt) |
DK (1) | DK2644698T3 (pt) |
ES (1) | ES2660151T3 (pt) |
FR (1) | FR18C1031I2 (pt) |
HK (1) | HK1223379A1 (pt) |
HR (1) | HRP20180421T1 (pt) |
HU (2) | HUE038305T2 (pt) |
LT (2) | LT2644698T (pt) |
LU (1) | LUC00076I2 (pt) |
MX (1) | MX355060B (pt) |
MY (1) | MY166429A (pt) |
NL (1) | NL300940I2 (pt) |
NO (2) | NO2644698T3 (pt) |
PH (1) | PH12016502073A1 (pt) |
PL (1) | PL2644698T3 (pt) |
PT (1) | PT2644698T (pt) |
RS (1) | RS57038B1 (pt) |
RU (3) | RU2620071C2 (pt) |
SI (1) | SI2644698T1 (pt) |
TR (1) | TR201802772T4 (pt) |
TW (4) | TW201631153A (pt) |
WO (1) | WO2012067176A1 (pt) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050086628A (ko) * | 2002-11-15 | 2005-08-30 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
EP4342995A3 (en) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
WO2009131553A2 (en) | 2006-12-29 | 2009-10-29 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
PT2129396E (pt) * | 2007-02-16 | 2013-11-18 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
AR068563A1 (es) | 2007-09-26 | 2009-11-18 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
WO2009041643A1 (ja) * | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
EP3674317A1 (en) | 2009-03-19 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
ES2777901T3 (es) * | 2009-12-25 | 2020-08-06 | Chugai Pharmaceutical Co Ltd | Método de modificación de polipéptidos para purificar multímeros polipeptídicos |
TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
EA037392B1 (ru) * | 2010-05-14 | 2021-03-23 | Эмджен Инк. | Композиции с высокой концентрацией антител |
PT2644698T (pt) | 2010-11-17 | 2018-01-31 | Chugai Pharmaceutical Co Ltd | Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue |
PT2647707T (pt) | 2010-11-30 | 2018-11-15 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de toxicidade |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
ES2732712T3 (es) | 2011-10-31 | 2019-11-25 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera |
WO2013170168A1 (en) | 2012-05-10 | 2013-11-14 | Bioatla Llc | Multi-specific monoclonal antibodies |
TR201910744T4 (tr) * | 2012-09-26 | 2019-08-21 | Univ Wuerzburg J Maximilians | Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar. |
EP2902787B1 (en) | 2012-09-28 | 2018-03-28 | Chugai Seiyaku Kabushiki Kaisha | Method for evaluating blood coagulation reaction |
ES2683268T3 (es) * | 2013-07-25 | 2018-09-25 | Cytomx Therapeutics, Inc. | Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y métodos para usar los mismos |
AU2014325063B2 (en) | 2013-09-27 | 2019-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
EA034655B1 (ru) * | 2013-11-06 | 2020-03-03 | Янссен Байотек, Инк. | Антитела к ccl17 |
US11072647B2 (en) * | 2013-12-19 | 2021-07-27 | Onsejo Nacional DE Investigation Cientiticay Tecnica | TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro |
BR112016015140A2 (pt) * | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
WO2015120138A2 (en) * | 2014-02-05 | 2015-08-13 | Dana-Farber Cancer Institute, Inc. | AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF |
HUE047398T2 (hu) * | 2014-03-26 | 2020-04-28 | Univ Wuerzburg J Maximilians | Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére |
CN105294857B (zh) * | 2014-06-18 | 2019-02-19 | 上海交通大学 | 基于fix的抗原表位及其应用 |
WO2015196142A1 (en) * | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
TW201625299A (zh) * | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
KR102504758B1 (ko) * | 2014-07-16 | 2023-02-28 | 트랜스진 | 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물 |
JP6858559B2 (ja) | 2014-08-20 | 2021-04-14 | 中外製薬株式会社 | 蛋白質溶液の粘度測定方法 |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
TWI701435B (zh) * | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
WO2016075612A1 (en) * | 2014-11-12 | 2016-05-19 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
US10849862B2 (en) * | 2014-12-26 | 2020-12-01 | Theravalues Corporation | Formulation of curcumin and anti-PD-1 antibody |
EP3252074A4 (en) * | 2015-01-30 | 2018-07-11 | Saitama Medical University | Anti-alk2 antibody |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
EP3258959A4 (en) * | 2015-02-22 | 2018-10-17 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd137 |
ES2886114T3 (es) * | 2015-03-31 | 2021-12-16 | Medimmune Ltd | Una nueva forma de IL33, formas mutadas de IL33, anticuerpos, ensayos y métodos para usar los mismos |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
KR102057767B1 (ko) | 2015-04-17 | 2019-12-19 | 에프. 호프만-라 로슈 아게 | 응고 인자 및 다중특이적 항체의 조합 요법 |
WO2016170944A1 (ja) * | 2015-04-24 | 2016-10-27 | 公立大学法人奈良県立医科大学 | 血液検体の凝固能の評価方法、並びにその方法に用いるための試薬、試薬キット及び装置 |
JP2018123055A (ja) * | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第viii因子(fviii)の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第xi因子(fxi)異常症の予防および/または治療に用いられる医薬組成物 |
MX2017015380A (es) | 2015-05-29 | 2018-03-28 | Amphivena Therapeutics Inc | Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33. |
WO2017022651A1 (ja) | 2015-07-31 | 2017-02-09 | 中外製薬株式会社 | アニオン性ポリマーによる抗体を含有する組成物の精製方法 |
BR112018002432A2 (pt) | 2015-09-18 | 2018-09-18 | Chugai Pharmaceutical Co Ltd | anticorpos de ligação à il-8 e usos dos mesmos |
KR20180071376A (ko) * | 2015-11-17 | 2018-06-27 | 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 | Pd-l1 항체, 이의 항원-결합 단편 및 이의 약제학적 용도 |
US20200270363A1 (en) | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
EP3402516A4 (en) * | 2016-01-12 | 2020-01-08 | Palleon Pharmaceuticals Inc. | USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER |
JP7320943B2 (ja) | 2016-04-28 | 2023-08-04 | 中外製薬株式会社 | 抗体含有製剤 |
CN113372446A (zh) * | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
WO2017216724A1 (en) * | 2016-06-15 | 2017-12-21 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
CN117683135A (zh) * | 2016-07-14 | 2024-03-12 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
CN109415444B (zh) * | 2016-07-29 | 2024-03-01 | 中外制药株式会社 | 显示增加的备选fviii辅因子功能活性的双特异性抗体 |
KR20240065318A (ko) | 2016-09-01 | 2024-05-14 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
SG11201901961SA (en) * | 2016-09-06 | 2019-04-29 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
DK3515478T3 (da) * | 2016-09-21 | 2024-05-21 | Nextcure Inc | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf |
CN110023339A (zh) * | 2016-09-23 | 2019-07-16 | Csl有限公司 | 凝血因子结合蛋白及其应用 |
SG10201913470SA (en) | 2016-11-08 | 2020-03-30 | Regeneron Pharma | Antigen-binding proteins that antagonize leptin receptor |
WO2018098363A2 (en) * | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
EP3868780A1 (en) * | 2016-12-21 | 2021-08-25 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
EP3574017A1 (en) * | 2017-01-27 | 2019-12-04 | Kymab Limited | Anti-opg antibodies |
EP3848396A1 (en) | 2017-02-01 | 2021-07-14 | Novo Nordisk A/S | Antibodies recognising factor ix and x for use in promoting coagulation |
CA3053231A1 (en) * | 2017-02-16 | 2018-08-23 | Xbiotech Inc. | Treatment of hidradenitis suppurativa |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
EP3603670A4 (en) | 2017-03-31 | 2021-03-10 | Public University Corporation Nara Medical University | MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII |
JP7314115B2 (ja) * | 2017-03-31 | 2023-07-25 | セレクティス ソシエテ アノニム | ユニバーサル抗cd22キメラ抗原受容体操作免疫細胞 |
CN110650976B (zh) * | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
AU2018273174B2 (en) * | 2017-05-26 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and related methods |
JP7257971B6 (ja) * | 2017-06-01 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用 |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
TWI726228B (zh) * | 2017-08-09 | 2021-05-01 | 國立臺灣大學 | Cd14拮抗分子用於治療癌症 |
CN111065649A (zh) * | 2017-08-16 | 2020-04-24 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和egfr、hla-e、ccr4或pd-l1的蛋白质 |
AU2018321359B2 (en) | 2017-08-22 | 2023-11-30 | Sanabio, Llc | Soluble interferon receptors and uses thereof |
AU2018335955A1 (en) * | 2017-09-21 | 2020-03-26 | Centre National De La Recherche Scientifique - Cnrs - | Antibodies having specificity for BTN2 and uses thereof |
MA50667A (fr) * | 2017-09-29 | 2020-08-05 | Chugai Pharmaceutical Co Ltd | Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif |
RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
CN111479829A (zh) | 2017-11-01 | 2020-07-31 | 中外制药株式会社 | 具有降低的生物活性的抗体变体和同种型 |
US11787874B2 (en) | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
WO2019104157A1 (en) * | 2017-11-21 | 2019-05-31 | The University Of Vermont And State Agricultural College | Highly specific zika neutralizing human antibodies |
SG11202005146VA (en) | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
RU2758378C1 (ru) * | 2018-02-09 | 2021-10-28 | Галдерма Холдинг СА | Немолизумаб в лечении атопического дерматита с экскориацией от умеренной до тяжелой |
WO2019177138A1 (ja) * | 2018-03-16 | 2019-09-19 | 国立大学法人滋賀医科大学 | 異常tdp-43を分解除去する抗体断片 |
WO2019195796A1 (en) * | 2018-04-06 | 2019-10-10 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
BR112020022655A2 (pt) * | 2018-05-09 | 2021-02-17 | Good T Cells, Inc. | epítopo de antígeno de superfície de células t reguladoras e anticorpo que se liga especificamente ao mesmo |
CN112512480A (zh) | 2018-05-21 | 2021-03-16 | 中外制药株式会社 | 被封入玻璃容器的冷冻干燥制剂 |
EP3805112A4 (en) | 2018-05-28 | 2022-03-09 | Chugai Seiyaku Kabushiki Kaisha | FILLING NOZZLE |
WO2019235420A1 (ja) | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | 複合体を検出する方法 |
WO2019238713A2 (en) * | 2018-06-13 | 2019-12-19 | Kymab Limited | Treatments etc |
FR3082427B1 (fr) | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x |
TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類pd-l1之抗體及其用途 |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
EP3830135A1 (en) * | 2018-08-01 | 2021-06-09 | Novo Nordisk A/S | Improved procoagulant antibodies |
TWI803682B (zh) * | 2018-08-20 | 2023-06-01 | 美商輝瑞股份有限公司 | 抗-gdf15抗體、組成物及使用方法 |
CA3123177A1 (en) * | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
KR20210107721A (ko) * | 2018-12-21 | 2021-09-01 | 23앤드미 인코포레이티드 | 항-il-36 항체 및 이의 사용 방법 |
KR20210143246A (ko) * | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
KR20220004979A (ko) * | 2019-03-27 | 2022-01-12 | 유엠씨 우트레크트 홀딩 비.브이. | 조작된 iga 항체 및 사용 방법 |
CN113692415A (zh) * | 2019-04-17 | 2021-11-23 | 诺和诺德股份有限公司 | 双特异性抗体 |
US11813311B2 (en) * | 2019-05-03 | 2023-11-14 | Singapore Health Services Pte Ltd. | Treatment and prevention of metabolic diseases |
JP7122354B2 (ja) * | 2019-09-24 | 2022-08-19 | 財團法人工業技術研究院 | 抗tigit抗体および使用方法 |
WO2021070885A1 (ja) | 2019-10-11 | 2021-04-15 | 中外製薬株式会社 | 後天性血友病aの予防および/または治療に用いられる医薬組成物、および当該医薬組成物を含む製品 |
IL292106A (en) | 2019-10-11 | 2022-06-01 | Chugai Pharmaceutical Co Ltd | A pharmaceutical composition that can be used to prevent and/or treat acquired hemophilia a, and a product that includes this pharmaceutical composition |
KR20220079652A (ko) | 2019-10-11 | 2022-06-13 | 에프. 호프만-라 로슈 아게 | 약물 투약 결정 디바이스 및 방법 |
US11890353B2 (en) * | 2019-10-15 | 2024-02-06 | Northwestern University | Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies |
CN115052898A (zh) | 2020-01-30 | 2022-09-13 | 诺和诺德股份有限公司 | 双特异性因子viii模拟抗体 |
AU2020260519A1 (en) * | 2020-03-23 | 2021-10-07 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
EP4132969A4 (en) * | 2020-04-07 | 2024-05-01 | Fred Hutchinson Cancer Center | ANTI-MESOTHELIN ANTIGEN BINDING MOLECULES AND THEIR USES |
JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
EP4138911A1 (en) * | 2020-04-24 | 2023-03-01 | Millennium Pharmaceuticals, Inc. | Anti-cd19 antibodies and uses thereof |
CR20220598A (es) * | 2020-04-30 | 2023-01-17 | Genentech Inc | Anticuerpos específicos para kras y sus usos |
JP2023527775A (ja) * | 2020-05-22 | 2023-06-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4r阻害剤の投与により好酸球性食道炎を処置する方法 |
CN115667515A (zh) | 2020-05-22 | 2023-01-31 | 中外制药株式会社 | 中和具有凝血因子viii(f.viii)功能替代活性的物质的抗体 |
WO2022031869A2 (en) * | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Gp130 binding molecules and methods of use |
US11505611B2 (en) * | 2020-08-21 | 2022-11-22 | Genzyme Corporation | FGFR3 antibodies and methods of use |
US11739137B2 (en) * | 2020-10-30 | 2023-08-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Single domain antibodies to SARS-CoV-2 nucleocapsid protein |
EP4313309A1 (en) * | 2021-03-22 | 2024-02-07 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
US20220348659A1 (en) * | 2021-03-24 | 2022-11-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
KR20240001704A (ko) * | 2021-04-23 | 2024-01-03 | 아스트라제네카 아베 | 항-i형 inf 수용체 항체 아니프롤루맙을 이용한 루푸스 신염의 치료 |
JPWO2023058723A1 (pt) | 2021-10-08 | 2023-04-13 | ||
KR20230130558A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 |
KR20230130560A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 |
KR20230130561A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 |
WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
Family Cites Families (233)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
JPS5824836B2 (ja) | 1974-10-14 | 1983-05-24 | ノウミボウサイコウギヨウ カブシキガイシヤ | カサイナドノツウホウソウチ |
JPS5334319A (en) | 1976-09-12 | 1978-03-30 | Nat Jutaku Kenzai | Entrance device of unit residence |
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
JPS59162441U (ja) | 1983-04-14 | 1984-10-31 | 千代田紙業株式会社 | 吹込口を有する重包包装 |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
JPH0764879B2 (ja) | 1984-01-12 | 1995-07-12 | チロン コ−ポレイシヨン | フアクタ−v▲iii▼cに対するモノクロ−ナル抗体 |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPH06104071B2 (ja) | 1986-08-24 | 1994-12-21 | 財団法人化学及血清療法研究所 | 第▲ix▼因子コンホメ−シヨン特異性モノクロ−ナル抗体 |
JPH0338228Y2 (pt) | 1986-09-26 | 1991-08-13 | ||
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
IL89491A0 (en) | 1988-11-17 | 1989-09-10 | Hybritech Inc | Bifunctional chimeric antibodies |
JPH0646389Y2 (ja) | 1989-05-12 | 1994-11-30 | ナショナル住宅産業株式会社 | ハンドグリップ取付構造 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ATE177321T1 (de) | 1989-12-11 | 1999-03-15 | Immunomedics Inc | Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
TW212184B (pt) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
JPH05184383A (ja) | 1990-06-19 | 1993-07-27 | Dainabotsuto Kk | 二重特異性抗体 |
JPH05199894A (ja) | 1990-08-20 | 1993-08-10 | Takeda Chem Ind Ltd | 二重特異性抗体および抗体含有薬剤 |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
DE122009000019I1 (de) | 1991-04-25 | 2009-07-16 | Chugai Seiyaku K K 5 1 | Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor |
JPH05304992A (ja) | 1991-06-20 | 1993-11-19 | Takeda Chem Ind Ltd | ハイブリッド・モノクローナル抗体および抗体含有薬剤 |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
JPH0767688B2 (ja) | 1992-01-21 | 1995-07-26 | 近畿コンクリート工業株式会社 | Pcコンクリートパネル |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
JPH05203652A (ja) | 1992-01-28 | 1993-08-10 | Fuji Photo Film Co Ltd | 抗体酵素免疫分析法 |
JPH05213775A (ja) | 1992-02-05 | 1993-08-24 | Otsuka Pharmaceut Co Ltd | Bfa抗体 |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
EP0584348B1 (en) | 1992-03-11 | 2005-05-18 | Powderject Vaccines, Inc. | Genetic vaccine for immunodeficiency viruses |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
ZA936260B (en) | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
EP0660937A1 (en) | 1993-07-01 | 1995-07-05 | Dade International Inc. | Process for the preparation of factor x depleted plasma |
FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
EP0771216B9 (en) | 1994-07-11 | 2003-01-02 | The Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of tumoral vasculature |
AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
CZ296919B6 (cs) | 1994-10-07 | 2006-07-12 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutický prípravek pro lécení chronické revmatické artritidy |
WO1996012503A1 (fr) | 1994-10-21 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Remede contre des maladies provoquees par la production d'il-6 |
EP1241264A1 (en) | 1994-12-02 | 2002-09-18 | Chiron Corporation | Monoclonal antibodies to colon cancer antigen |
US6485943B2 (en) | 1995-01-17 | 2002-11-26 | The University Of Chicago | Method for altering antibody light chain interactions |
AU4865296A (en) | 1995-02-28 | 1996-09-18 | Procter & Gamble Company, The | Preparation of noncarbonated beverage products having superior microbial stability |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU690474B2 (en) | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
EP0938499A1 (en) | 1996-07-19 | 1999-09-01 | Amgen Inc. | Analogs of cationic proteins |
JPH10165184A (ja) | 1996-12-16 | 1998-06-23 | Tosoh Corp | 抗体、遺伝子及びキメラ抗体の製法 |
US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
CA2288600C (en) * | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
US5980893A (en) | 1997-07-17 | 1999-11-09 | Beth Israel Deaconess Medical Center, Inc. | Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis |
US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
WO1999018212A1 (fr) | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain naturel |
CN1073412C (zh) | 1998-03-19 | 2001-10-24 | 中国科学院化学研究所 | 一种高分子微包囊的制备方法 |
BR9909382A (pt) | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
MXPA01005515A (es) | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Anticuerpos humanizados para gamma-interferon. |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
EP1074842A1 (en) | 1999-07-21 | 2001-02-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Catalytic anti-factor VIII allo-antibodies |
NL1012907C2 (nl) * | 1999-08-25 | 2001-02-27 | Amb It Holding Bv | Stelsel voor het bepalen van de positie van een transponder. |
AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
SE9903895D0 (sv) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
JP2004505609A (ja) | 2000-04-03 | 2004-02-26 | オックスフォード グリコサイエンシズ(ユーケー) リミテッド | 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用 |
AU2001266272B2 (en) | 2000-05-03 | 2005-09-15 | Medigene Ag | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
US20020103345A1 (en) | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
US7160540B2 (en) | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
WO2002006838A1 (fr) | 2000-07-17 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Methode de criblage d'un ligand dote d'une activite biologique |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
AU1091802A (en) | 2000-10-20 | 2002-04-29 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibody |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
JP2005500018A (ja) | 2001-04-02 | 2005-01-06 | アイデック ファーマスーティカルズ コーポレイション | GnTIIIと同時発現する組換え抗体 |
PL367324A1 (en) | 2001-04-13 | 2005-02-21 | Biogen, Inc. | Antibodies to vla-1 |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
KR100877176B1 (ko) | 2001-06-22 | 2009-01-07 | 츄가이 세이야꾸 가부시키가이샤 | 항글리피칸 3항체를 포함하는 세포증식 억제제 |
US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US20030190705A1 (en) | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
CA2472922A1 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
JP4386741B2 (ja) | 2002-04-15 | 2009-12-16 | 中外製薬株式会社 | scDbライブラリーの作成方法 |
US7732149B2 (en) | 2002-04-26 | 2010-06-08 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening agonistic antibodies |
EP1510943A4 (en) | 2002-05-31 | 2007-05-09 | Celestar Lexico Sciences Inc | INTERACTION PREDICTION DEVICE |
JP2004086862A (ja) | 2002-05-31 | 2004-03-18 | Celestar Lexico-Sciences Inc | タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体 |
EP1511861A4 (en) | 2002-06-12 | 2007-12-05 | Genencor Int | METHODS AND BINDING COMPOSITIONS DEPENDENT FROM THE MEDIUM OF A TARGET AGENT TO A TARGET |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
CA2492524A1 (en) | 2002-08-15 | 2004-02-26 | Epitomics, Inc. | Humanized rabbit antibodies |
CA2501571A1 (en) | 2002-10-07 | 2004-04-15 | Mempile Inc. | Tight focusing method and system |
GB0224082D0 (en) | 2002-10-16 | 2002-11-27 | Celltech R&D Ltd | Biological products |
JPWO2004060919A1 (ja) | 2002-12-26 | 2006-05-11 | 中外製薬株式会社 | ヘテロ受容体に対するアゴニスト抗体 |
DE602004021095D1 (de) | 2003-01-21 | 2009-06-25 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening der leichten kette eines antikörpers |
US7223393B2 (en) | 2003-02-07 | 2007-05-29 | Pdl Biopharma, Inc | Amphiregulin antibodies and their use to treat cancer and psoriasis |
GB2400851B (en) | 2003-04-25 | 2004-12-15 | Bioinvent Int Ab | Identifying binding of a polypeptide to a polypeptide target |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
PT1631313E (pt) | 2003-06-05 | 2015-07-02 | Genentech Inc | Terapêutica de combinação para distúrbios de células b |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
JP2005101105A (ja) | 2003-09-22 | 2005-04-14 | Canon Inc | 位置決め装置、露光装置、デバイス製造方法 |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
AU2003271186A1 (en) | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
MXPA06005941A (es) | 2003-12-10 | 2006-08-23 | Medarex Inc | Anticuerpos ip-10 y sus usos. |
CA2546054C (en) | 2003-12-10 | 2014-05-13 | Medarex, Inc. | Interferon alpha antibodies and their uses |
US20050136051A1 (en) | 2003-12-22 | 2005-06-23 | Bernard Scallon | Methods for generating multimeric molecules |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
DK2177537T3 (da) | 2004-01-09 | 2011-12-12 | Pfizer | Antistoffer til MAdCAM |
CA2561264A1 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2005112564A2 (en) | 2004-04-15 | 2005-12-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Germline and sequence variants of humanized antibodies and methods of making and using them |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
AU2005259992A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune, Llc | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
AU2005272993B2 (en) | 2004-07-15 | 2010-02-11 | Xencor, Inc | Optimized Fc variants |
EP1778728A2 (en) | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
WO2006031994A2 (en) | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
CA2580319A1 (en) | 2004-09-14 | 2006-03-23 | National Institute For Biological Standards And Control | Vaccine |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
JP5787461B2 (ja) | 2004-12-14 | 2015-09-30 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 免疫グロブリンの精製方法 |
EP2208783A1 (en) | 2004-12-22 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
WO2006106903A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2構造異性体 |
US20100003254A1 (en) | 2005-04-08 | 2010-01-07 | Chugai Seiyaku Kabushiki Kaisha | Antibody Substituting for Function of Blood Coagulation Factor VIII |
RU2403261C2 (ru) | 2005-04-15 | 2010-11-10 | Дженентек, Инк. | Варианты бета-цепи hgf |
WO2006121852A2 (en) | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
CA2610987C (en) | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
EP3348639A3 (en) | 2005-06-10 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Sc(fv)2 site-directed mutant |
AU2006261920A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Llc | Antibody formulations having optimized aggregation and fragmentation profiles |
EP1915176A4 (en) | 2005-07-15 | 2008-12-03 | Univ Vermont | ULTRASENSITIVE IMMUNOASSAY AND ANTIBODIES FOR DETECTION OF BLOOD FACTOR VIII |
WO2007024535A2 (en) | 2005-08-19 | 2007-03-01 | Wyeth | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
WO2007060411A1 (en) | 2005-11-24 | 2007-05-31 | Ucb Pharma S.A. | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r |
EP4342995A3 (en) * | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
MY157796A (en) | 2006-06-08 | 2016-07-29 | Chugai Pharmaceutical Co Ltd | Preventive or remedy for inflammatory disease |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
WO2008090960A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
EP4119579A1 (en) | 2007-05-31 | 2023-01-18 | Genmab A/S | Stable igg4 antibodies |
CN101883793A (zh) | 2007-08-23 | 2010-11-10 | Lfb生物科技公司 | 中和针对因子ⅷ的c1结构域的抑制性抗体的抑制活性的抗独特型抗体 |
PE20091205A1 (es) | 2007-09-26 | 2009-09-09 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6 |
AR068563A1 (es) | 2007-09-26 | 2009-11-18 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
WO2009041643A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
KR20150126724A (ko) | 2007-09-28 | 2015-11-12 | 추가이 세이야쿠 가부시키가이샤 | 혈장 중 반응속도가 개선된 항-글리피칸-3 항체 |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
MX2010011717A (es) | 2008-05-01 | 2010-11-30 | Amgen Inc | Anticuerpos anti-hepcidina y metodos de uso. |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
EP3674317A1 (en) | 2009-03-19 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CN101906160A (zh) | 2009-06-05 | 2010-12-08 | 苏州泽璟生物制药有限公司 | 一种抗人凝血因子ⅷ单克隆抗体及其制备方法和用途 |
RU2522002C2 (ru) | 2009-06-26 | 2014-07-10 | Ридженерон Фармасьютикалз, Инк. | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом |
ES2777901T3 (es) * | 2009-12-25 | 2020-08-06 | Chugai Pharmaceutical Co Ltd | Método de modificación de polipéptidos para purificar multímeros polipeptídicos |
TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
JP5820800B2 (ja) | 2010-03-02 | 2015-11-24 | 協和発酵キリン株式会社 | 改変抗体組成物 |
SA111320266B1 (ar) | 2010-03-11 | 2015-06-21 | رينات نيوروساينس كوربوريشن | أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني |
KR20130018256A (ko) | 2010-03-31 | 2013-02-20 | 제이에스알 가부시끼가이샤 | 친화성 크로마토그래피용 충전제 |
KR101930964B1 (ko) | 2010-04-20 | 2018-12-19 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
RU2624027C2 (ru) | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Получение гетеромультимерных белков |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
BR112012031920A2 (pt) | 2010-06-14 | 2017-05-16 | Paion Deutschland Gmbh | tratamento de coagulopatias com hiperfibrinólise. |
EP2603526A1 (en) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
BR112013011811A2 (pt) | 2010-11-05 | 2023-02-23 | Zymeworks Inc | Modelo de anticorpo heterodimérico estável com mutações no domínio fc |
PT2644698T (pt) | 2010-11-17 | 2018-01-31 | Chugai Pharmaceutical Co Ltd | Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue |
EP2688909A2 (en) | 2011-03-25 | 2014-01-29 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
EP3674320A3 (en) | 2011-10-27 | 2020-08-12 | Genmab A/S | Production of heterodimeric proteins |
ES2732712T3 (es) | 2011-10-31 | 2019-11-25 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera |
RS62689B1 (sr) | 2011-11-04 | 2021-12-31 | Zymeworks Inc | Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu |
LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
BR112014019667B1 (pt) | 2012-03-08 | 2022-11-01 | F. Hoffmann-La Roche Ag | Formulação farmacêutica líquida estável de anticorpo abeta |
EP2825559B1 (en) | 2012-03-13 | 2019-02-27 | Novimmune SA | Readily isolated bispecific antibodies with native immunoglobulin format |
KR102382304B1 (ko) | 2012-04-20 | 2022-04-04 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
CA2881679C (en) | 2012-08-13 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
EP2902787B1 (en) | 2012-09-28 | 2018-03-28 | Chugai Seiyaku Kabushiki Kaisha | Method for evaluating blood coagulation reaction |
EP2905290B1 (en) | 2012-10-05 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Heterodimeric protein composition |
CA2889951C (en) | 2012-11-02 | 2023-04-18 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
KR102264570B1 (ko) | 2012-11-28 | 2021-06-14 | 자임워크스 인코포레이티드 | 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도 |
US20140377253A1 (en) | 2013-03-15 | 2014-12-25 | Abbvie Biotherapeutics Inc. | Fc variants |
AU2014325063B2 (en) | 2013-09-27 | 2019-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
CN105873953A (zh) | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP3107938B1 (en) | 2014-05-28 | 2022-05-04 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
TW201625299A (zh) | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
JP6630036B2 (ja) | 2014-09-30 | 2020-01-15 | Jsr株式会社 | 標的物の精製方法、及び、ミックスモード用担体 |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第viii因子(fviii)の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第xi因子(fxi)異常症の予防および/または治療に用いられる医薬組成物 |
US20200270363A1 (en) | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
JP7320943B2 (ja) | 2016-04-28 | 2023-08-04 | 中外製薬株式会社 | 抗体含有製剤 |
CA3025162A1 (en) | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
CN109476763B (zh) | 2016-07-19 | 2023-11-07 | 伊班绰斯有限责任公司 | 双特异性蛋白质及其制备方法 |
CN109415444B (zh) | 2016-07-29 | 2024-03-01 | 中外制药株式会社 | 显示增加的备选fviii辅因子功能活性的双特异性抗体 |
SG11201901961SA (en) | 2016-09-06 | 2019-04-29 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
MA50667A (fr) | 2017-09-29 | 2020-08-05 | Chugai Pharmaceutical Co Ltd | Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif |
-
2011
- 2011-11-17 PT PT118421452T patent/PT2644698T/pt unknown
- 2011-11-17 RU RU2013118448A patent/RU2620071C2/ru active
- 2011-11-17 TW TW105115923A patent/TW201631153A/zh unknown
- 2011-11-17 EP EP17200495.4A patent/EP3318633A1/en active Pending
- 2011-11-17 NO NO11842145A patent/NO2644698T3/no unknown
- 2011-11-17 HU HUE11842145A patent/HUE038305T2/hu unknown
- 2011-11-17 KR KR1020137018781A patent/KR101398363B1/ko active Protection Beyond IP Right Term
- 2011-11-17 TW TW100141973A patent/TWI629355B/zh active
- 2011-11-17 US US13/885,421 patent/US9334331B2/en active Active
- 2011-11-17 BR BR112013012213-7A patent/BR112013012213A2/pt not_active Application Discontinuation
- 2011-11-17 KR KR1020137018788A patent/KR101398290B1/ko active IP Right Grant
- 2011-11-17 JP JP2012544291A patent/JP6013915B2/ja active Active
- 2011-11-17 SI SI201131447T patent/SI2644698T1/en unknown
- 2011-11-17 TW TW102146540A patent/TWI452135B/zh active
- 2011-11-17 AU AU2011330184A patent/AU2011330184B2/en active Active
- 2011-11-17 PL PL11842145T patent/PL2644698T3/pl unknown
- 2011-11-17 TR TR2018/02772T patent/TR201802772T4/tr unknown
- 2011-11-17 LT LTEP11842145.2T patent/LT2644698T/lt unknown
- 2011-11-17 PH PH12016502073A patent/PH12016502073A1/en unknown
- 2011-11-17 TW TW102146541A patent/TWI452136B/zh active
- 2011-11-17 CN CN201180065133.1A patent/CN103298937B/zh active Active
- 2011-11-17 MX MX2013005394A patent/MX355060B/es active IP Right Grant
- 2011-11-17 ES ES11842145.2T patent/ES2660151T3/es active Active
- 2011-11-17 KR KR1020197007879A patent/KR102099580B1/ko active IP Right Grant
- 2011-11-17 DK DK11842145.2T patent/DK2644698T3/en active
- 2011-11-17 KR KR1020137013908A patent/KR101962483B1/ko active IP Right Grant
- 2011-11-17 WO PCT/JP2011/076486 patent/WO2012067176A1/ja active Application Filing
- 2011-11-17 CN CN201610299812.XA patent/CN105859889B/zh active Active
- 2011-11-17 EP EP11842145.2A patent/EP2644698B1/en active Active
- 2011-11-17 RS RS20180318A patent/RS57038B1/sr unknown
- 2011-11-17 CA CA2817964A patent/CA2817964C/en active Active
- 2011-11-17 MY MYPI2013700794A patent/MY166429A/en unknown
-
2013
- 2013-02-01 JP JP2013018255A patent/JP5246905B1/ja active Active
- 2013-02-01 JP JP2013018259A patent/JP5246906B1/ja active Active
- 2013-07-04 RU RU2013130595/10A patent/RU2534347C1/ru active
- 2013-07-04 RU RU2013130596A patent/RU2534564C3/ru active Protection Beyond IP Right Term
- 2013-09-05 US US14/019,117 patent/US20140370018A1/en not_active Abandoned
- 2013-09-06 US US14/019,712 patent/US20140037632A1/en not_active Abandoned
-
2016
- 2016-04-19 US US15/132,996 patent/US10450381B2/en active Active
- 2016-05-30 AU AU2016203564A patent/AU2016203564B2/en active Active
- 2016-09-23 JP JP2016185421A patent/JP6710131B2/ja active Active
- 2016-10-05 HK HK16111570.7A patent/HK1223379A1/zh unknown
- 2016-10-07 US US15/288,965 patent/US20170022293A1/en not_active Abandoned
-
2018
- 2018-03-09 HR HRP20180421TT patent/HRP20180421T1/hr unknown
- 2018-05-30 NL NL300940C patent/NL300940I2/nl unknown
- 2018-05-30 LU LU00076C patent/LUC00076I2/en unknown
- 2018-06-13 LT LTPA2018507C patent/LTC2644698I2/lt unknown
- 2018-06-21 HU HUS1800029C patent/HUS1800029I1/hu unknown
- 2018-07-19 FR FR18C1031C patent/FR18C1031I2/fr active Active
-
2019
- 2019-03-05 JP JP2019039114A patent/JP6823677B2/ja active Active
- 2019-07-02 US US16/459,791 patent/US20190315884A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021002057A patent/JP2021065233A/ja active Pending
-
2022
- 2022-04-26 US US17/729,471 patent/US20220267470A1/en not_active Abandoned
- 2022-10-12 JP JP2022163711A patent/JP2022191374A/ja active Pending
- 2022-12-15 US US18/081,874 patent/US20230212315A1/en not_active Abandoned
-
2023
- 2023-09-06 NO NO2023034C patent/NO2023034I1/no unknown
- 2023-10-27 US US18/495,861 patent/US20240059795A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1800029I1 (hu) | A VIII vérkoagulációs faktor mûködésére alternatív funkciójú multispecifikus antigén-kötõ molekula | |
CYD2019001I2 (el) | Διαμορφωση της εκφρασης τρανσθυρετινης | |
HK1214277A1 (zh) | 生產異源多聚體蛋白質 | |
SMT201600079B (it) | Composizioni per somministrazione mirata di sirna | |
CO6960555A2 (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
PT2663250T (pt) | Instrumento eletrocirúrgico | |
HK1178465A1 (en) | Composition for improving condition of skin | |
BR112014003878A2 (pt) | síntese de r-bifenilalaninol | |
FI20105825A (fi) | Veriryhmästatuksen käyttö III | |
GB2496735B (en) | Electrosurgical instrument | |
BR112013011858A2 (pt) | métodos para reforçar oxigenação de tecido comprometido | |
IL229742A0 (en) | Hyperforin analogues, methods for their production and their uses | |
DK2590565T3 (da) | Blodprøvetagning | |
SG10201605135YA (en) | Application of treatment fluids to components | |
FR2966344B1 (fr) | Orthese de cheville | |
EP2791349A4 (en) | SYNTHESIS OF N-ACETYL-D-NEURAMIC ACID | |
GB2492064B (en) | Electrosurgical instrument | |
DK2566505T3 (da) | Fremføring af kolesterylester til steroidogene væv | |
IL222903A0 (en) | Composition of small molecule therapeutices | |
BR112013014710A2 (pt) | entrega de compostos funcionais | |
BR112013007817A2 (pt) | síntese aperfeiçoada de peretinoin | |
BR112013007818A2 (pt) | síntese aperfeiçoada de peretinoin | |
PL395785A1 (pl) | Zastosowanie medyczne N-etylo-3-amino-4-fenylo-5-okso-2,5-dihydro-1H-pirazolo-1-karbotioamidu | |
TWM388919U (en) | Structure of endoscope | |
GB201211721D0 (en) | Improvements is or relating to urolgical catheters |